TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea

• Published in: Cancers Vol. 14; no. 19; p. 4928
• Main Authors: Kim, Min Jhi, Kim, Jin Kyong, Kim, Gi Jeong, Kang, Sang-Wook, Lee, Jandee, Jeong, Jong Ju, Chung, Woong Youn, Kim, Daham, Nam, Kee-Hyun
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-10-2022; MDPI
• Subjects: Binding sites; Coexistence; Genetic aspects; Health aspects; Iodine; Mutation; Mutation (Biology); Papillary thyroid cancer; Patients; RNA-directed DNA polymerase; Telomerase; Telomerase reverse transcriptase; Thyroglobulin; Thyroid cancer; Thyroidectomy; Tumors; South Korea; United States > US
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14194928

Telomerase reverse transcriptase (TERT) promoter mutation has been investigated for its clinical and prognostic significance in aggressive papillary thyroid cancer (PTC). In this study, we aimed to assess the prevalence, clinicopathologic features, and treatment outcomes of TERT mutation-positive PTCs along with the common BRAF V600E mutation. We performed mutational analyses for BRAF and the TERT promoter in thyroid cancer patients who had undergone surgery at our institution since 2019. We reviewed and analyzed 7797 patients with PTC in this study. The prevalence of BRAF V600E and TERT promoter mutations was 84.0% and 1.1%, respectively. Multifocal gene mutations in bilateral PTCs were identified. TERT promoter mutations were associated with older age, larger tumor size, tumor multifocality, tumor variants, advanced stages, more adjuvant radioactive iodine treatment (RAI), higher stimulated serum thyroglobulin level before RAI, and more uptakes in the regions outside the surgical field on a post-RAI whole-body scan. The coexistence of BRAF V600E and TERT promoter mutations exacerbated all clinicopathologic characteristics. The frequency of TERT promoter mutations was the lowest in this study, compared to previous studies. TERT promoter mutations consistently correlated with aggressive PTCs, and the synergistic effect of both mutations was evident. Specific clinical settings in our institution and in Korea may have led to these distinctive results. Prospective multicenter studies with longer follow-up periods are required to establish valuable oncologic outcomes.